Identification of Novel α-Synuclein Isoforms in Human Brain Tissue by using an Online NanoLC-ESI-FTICR-MS Method
暂无分享,去创建一个
Anders Wallin | Dag Aarsland | Henrik Zetterberg | Kaj Blennow | Clive Ballard | Eugeen Vanmechelen | Ann Westman-Brinkmalm | Gunnar Brinkmalm | K. Blennow | D. Aarsland | E. Vanmechelen | C. Ballard | H. Zetterberg | A. Öhrfelt | A. Wallin | E. Mulugeta | P. Francis | A. Westman-Brinkmalm | G. Brinkmalm | R. Persson | Paul T. Francis | Annika Öhrfelt | Kerstin Andersson | Rita Persson | Dzemila Secic | Ezra Mulugeta | K. Andersson | Dzemila Secic | A. Westman‐Brinkmalm
[1] K. Blennow,et al. Identification of novel N-terminal fragments of amyloid precursor protein in cerebrospinal fluid , 2010, Experimental Neurology.
[2] M. Weiner,et al. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.
[3] Aneeka M Hancock,et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. , 2010, Brain : a journal of neurology.
[4] Thomas Foltynie,et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. , 2009, Brain : a journal of neurology.
[5] David R. Williams,et al. Biological fluid biomarkers in neurodegenerative parkinsonism , 2009, Nature Reviews Neurology.
[6] W. M. van der Flier,et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.
[7] K. Blennow,et al. Cerebrospinal fluid α-synuclein in neurodegenerative disorders—A marker of synapse loss? , 2009, Neuroscience Letters.
[8] S. Lorenzl,et al. Increased α-synuclein aggregation following limited cleavage by certain matrix metalloproteinases , 2009, Experimental Neurology.
[9] J. Winderickx,et al. Phosphorylation, lipid raft interaction and traffic of alpha-synuclein in a yeast model for Parkinson. , 2008, Biochimica et biophysica acta.
[10] B. Mollenhauer,et al. Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration , 2008, Experimental Neurology.
[11] L. Lopiano,et al. α-synuclein and Parkinson’s disease: a proteomic view , 2008, Expert review of proteomics.
[12] A. C. Belin,et al. Parkinson’s disease: A genetic perspective , 2008, The FEBS journal.
[13] G. Halliday,et al. Human-based studies on α-synuclein deposition and relationship to Parkinson's disease symptoms , 2008, Experimental Neurology.
[14] G. Halliday,et al. Human-based studies on alpha-synuclein deposition and relationship to Parkinson's disease symptoms. , 2008, Experimental neurology.
[15] I. Ferrer,et al. Identification and characterization of a new alpha-synuclein isoform and its role in Lewy body diseases , 2008, Neurogenetics.
[16] Henrik Zetterberg,et al. Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. , 2007, Journal of proteome research.
[17] N. Kelleher,et al. Decoding protein modifications using top-down mass spectrometry , 2007, Nature Methods.
[18] R. Nelson,et al. Investigation of Human Protein Variants and Their Frequency in the General Population*S , 2007, Molecular & Cellular Proteomics.
[19] K. Blennow,et al. Aspects of beta-amyloid as a biomarker for Alzheimer's disease. , 2007, Biomarkers in medicine.
[20] E. Perry,et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum , 2006, Neurology.
[21] R. Barbour,et al. Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein in Familial and Sporadic Lewy Body Disease* , 2006, Journal of Biological Chemistry.
[22] M. Onofrj,et al. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium , 2006, Neurology.
[23] A. Delacourte,et al. Biochemical Staging of Synucleinopathy and Amyloid Deposition in Dementia With Lewy Bodies , 2006, Journal of neuropathology and experimental neurology.
[24] J. Growdon,et al. Clinical and biochemical correlates of insoluble alpha-synuclein in dementia with Lewy bodies. , 2006, Acta neuropathologica.
[25] J. Growdon,et al. Clinical and biochemical correlates of insoluble α-synuclein in dementia with Lewy bodies , 2006, Acta Neuropathologica.
[26] N. Hattori,et al. A Combinatorial Code for the Interaction of α-Synuclein with Membranes* , 2005, Journal of Biological Chemistry.
[27] N. Hattori,et al. A combinatorial code for the interaction of alpha-synuclein with membranes. , 2005, The Journal of biological chemistry.
[28] D. Lynch,et al. Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. , 2004, The Journal of biological chemistry.
[29] Hansjürgen Bratzke,et al. Stages in the development of Parkinson’s disease-related pathology , 2004, Cell and Tissue Research.
[30] Robert Edwards,et al. Lipid Rafts Mediate the Synaptic Localization of α-Synuclein , 2004, The Journal of Neuroscience.
[31] S. Deininger,et al. "Affinity-proteomics": direct protein identification from biological material using mass spectrometric epitope mapping , 2004, Analytical and bioanalytical chemistry.
[32] R. Edwards,et al. Lipid rafts mediate the synaptic localization of alpha-synuclein. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[33] H. Braak,et al. Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.
[34] B. Ghetti,et al. Ubiquitination of α-Synuclein in Lewy Bodies Is a Pathological Event Not Associated with Impairment of Proteasome Function* , 2003, Journal of Biological Chemistry.
[35] P. Axelsen,et al. Role of α-Synuclein Carboxy-Terminus on Fibril Formation in Vitro† , 2003 .
[36] J. Trojanowski,et al. Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. , 2003, Biochemistry.
[37] J. George,et al. The synucleins , 2001, Genome Biology.
[38] C. Masters,et al. The solubility of α‐synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease , 2001 .
[39] C. Masters,et al. The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease. , 2001, Journal of neurochemistry.
[40] C. Masters,et al. Accumulation of Insoluble α-Synuclein in Dementia with Lewy Bodies , 2000, Neurobiology of Disease.
[41] C. Masters,et al. Accumulation of insoluble alpha-synuclein in dementia with Lewy bodies. , 2000, Neurobiology of disease.
[42] B. Hyman,et al. Clinicopathologic correlates in temporal cortex in dementia with Lewy bodies , 1999, Neurology.
[43] J Q Trojanowski,et al. Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. , 1998, The American journal of pathology.
[44] P. Blumbergs,et al. Multiple-system atrophy: a new α-synuclein disease? , 1998, The Lancet.
[45] Nigel J. Cairns,et al. Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies , 1998, Neuroscience Letters.
[46] J Q Trojanowski,et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. , 1998, The American journal of pathology.
[47] R A Crowther,et al. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. , 1998, Neuroscience letters.
[48] R. Krüger,et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.
[49] P. Blumbergs,et al. Multiple-system atrophy: a new alpha-synuclein disease? , 1998, Lancet.
[50] Robert L. Nussbaum,et al. Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .
[51] S E Ide,et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.
[52] M G Spillantini,et al. Alpha-synuclein in Lewy bodies. , 1997, Nature.
[53] K. Jellinger,et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. , 1996, Neurology.
[54] R. Heilig,et al. The NACP/synuclein gene: chromosomal assignment and screening for alterations in Alzheimer disease. , 1995, Genomics.
[55] Michel Goedert,et al. Identification of two distinct synucleins from human brain , 1994, FEBS letters.
[56] E. Masliah,et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[57] S. M. Sumi,et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.
[58] R. Bradshaw,et al. Protein translocation and turnover in eukaryotic cells. , 1989, Trends in biochemical sciences.
[59] R. Mohs,et al. Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. , 2002, Psychopharmacology bulletin.
[60] R. Scheller,et al. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[61] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.